Who is the manufacturer of tamiflu

Become an underwriter». All rights reserved. The University of Minnesota is an equal opportunity educator and employer. Skip to main content. University of Minnesota. Driven to Discover. Site Search. Staff Mission Contact Us. Avian Influenza Bird Flu. Business Preparedness. Influenza, General.

Oct 18, Share this page:. Sign up now». Related News All news. Sep 30 In both statistically significant studies at the recommended dose, there was a 1. The most frequently reported adverse events in these studies in patients taking TAMIFLU were nausea and vomiting and, to a lesser extent, bronchitis, insomnia, and vertigo. These events were generally mild to moderate and transient. However, when taken with food, tolerability may be enhanced in some patients. Also, no overall difference in safety was observed in clinical trials between the elderly patients and younger adults, and no dose adjustments are required when treating these populations.

This early outbreak, coupled with predictions of a severe flu season, makes TAMIFLU a welcome treatment alternative to managing the misery of the flu. Each year, up to 40 million Americans develop the flu, an average of about , are hospitalized, and 20, to 40, people die from influenza and its complications. It also claimed that the drug could induce some side effects including renal and psychiatric events, and serious heart rhythm problems.

The report based these conclusions on 46 trials that included 20 oseltamivir and 26 zanamivir traded as Relenza studies. The Group, however, also disclosed that many of the studies had design flaws and hence their conclusions could not be definitive. Tamiflu is found to reduce the duration of influenza illness when consumed as per approved dosage 75mg twice daily for five days. In otherwise healthy individuals the drug reduces the severity of symptoms and infections such as bronchitis.

In children it reduces the likelihood of febrile influenza and also the incidence of associated otitis media.

Laboratory clinical studies have proven Tamiflu to be effective against the H5N1 virus in animals infected with the H5N1 strain taken from humans. These reports suggest that the drug is beneficial when administered within 48 hours of symptoms beginning.

The clinical trials on efficacy of the drug for influenza treatment comprised two placebo-controlled and double-blind clinical trials on adult patients, three double-blind placebo-controlled treatment trials on geriatric patients, and one double-blind placebo-controlled treatment trial on paediatric patients.

The trial results in all three categories indicated the efficacy of Tamiflu in treating influenza virus types A and B equally in males and females. The trials on prophylaxis of naturally occurring influenza involved three seasonal studies and a post-exposure prophylaxis study in adult households, and a randomised, open-label, post-exposure prophylaxis study on paediatric households including children aged one to 12 years as family contacts and index cases.

In these trials Tamiflu was found to be effective in reducing the incidences of laboratory-confirmed influenza. A person who accompanied a H1N1 influenza patient contracted the virus even after Tamiflu was administered for flu prevention.